Fate Therapeutics Files 8-K Report
Ticker: FATE · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-K, regulatory
Related Tickers: FATE
TL;DR
Fate Therapeutics filed an 8-K, likely with financial updates. Check for details.
AI Summary
On October 26, 2025, Fate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates Fate Therapeutics is providing updated information to the SEC, which could include financial details or other corporate events relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not, in this excerpt, detail any specific negative or positive material events.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- October 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36076 (identifier) — SEC File Number
- 65-1311552 (identifier) — IRS Employer Identification No.
- 12278 Scripps Summit Drive (address) — Principal Executive Offices
- San Diego (location) — Principal Executive Offices City
- California (location) — Principal Executive Offices State
- 92131 (zip_code) — Principal Executive Offices Zip Code
- 858 875-1800 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Fate Therapeutics?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it's for reporting purposes, including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 26, 2025.
Where are Fate Therapeutics, Inc.'s principal executive offices located?
Fate Therapeutics, Inc.'s principal executive offices are located at 12278 Scripps Summit Drive, San Diego, California, 92131.
What is the SEC file number for Fate Therapeutics, Inc.?
The SEC file number for Fate Therapeutics, Inc. is 001-36076.
What is the IRS Employer Identification Number for Fate Therapeutics, Inc.?
The IRS Employer Identification Number for Fate Therapeutics, Inc. is 65-1311552.
Filing Stats: 1,616 words · 6 min read · ~5 pages · Grade level 17.7 · Accepted 2025-10-27 07:00:13
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FATE Nasdaq Global Market
Filing Documents
- d36426d8k.htm (8-K) — 34KB
- d36426dex991.htm (EX-99.1) — 30KB
- 0001193125-25-250674.txt ( ) — 185KB
- fate-20251026.xsd (EX-101.SCH) — 3KB
- fate-20251026_lab.xml (EX-101.LAB) — 17KB
- fate-20251026_pre.xml (EX-101.PRE) — 11KB
- d36426d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's beliefs and expectations regarding: the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the safety and therapeutic potential of the Company's product candidates, including FT819, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the Company's plans to complete Investigational New Drug (IND)-enabling studies and to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the availability of data from the Company's clinical trials and the Company's plans to provide updates on its clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, and the Company's clinical and product development strategy. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "hope," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These and any other forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause our actual results to differ materially and
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FATE THERAPEUTICS, INC. Date: October 27, 2025 By: /s/ Bahram Valamehr Bahram Valamehr, Ph.D., M.B.A. President and Chief Executive Officer